Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13943113 | 0.99 | BDKRB1 (0.73) | BDKRB1 | |
| SCHEMBL13939534 | 0.98 | BDKRB1 (0.74) | BDKRB1 | |
| SCHEMBL12794314 | 0.90 | BDKRB1 (0.73) | BDKRB1 | |
| SCHEMBL1179975 | 0.89 | BDKRB1 (0.67) | BDKRB1 | |
| SCHEMBL12916029 | 0.88 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL12730927 | 0.88 | BDKRB1 (0.77) | BDKRB1 | |
| SCHEMBL12010320 | 0.88 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL15372728 | 0.88 | BDKRB1 (0.75) | BDKRB1 | |
| SCHEMBL3440541 | 0.88 | BDKRB1 (0.75) | BDKRB1 | |
| SCHEMBL12010306 | 0.88 | BDKRB1 (0.62) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394805-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110098282-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| EP-2284166-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021944-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098282-A1 | NEW COMPOUNDS | BRDT, AURKAIP1, ABCG2 | BDKRB1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.